Man Group’s Prevail Therapeutics Inc. Common Stock PRVL Stock Holding History

Man Group’s Portfolio PRVL Stock Details PRVL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-200,000	Closed	-$4.61M	–	2093
2020 Q4	$4.61M	Buy	+200,000	New	+$2.53M	0.02%	852

Man Group's PRVL Position: Q1 2021 in Review

Man Group sold out of Prevail Therapeutics Inc. Common Stock (PRVL) in Q1 2021, closing a stake of 200,000 shares — an estimated $4.61M sold.

Man Group first reported a position in PRVL in Q4 2020 and held it in 1 quarter. The position peaked at $4.61M in Q4 2020. 0 funds tracked by Wall St. Rank hold PRVL as of Q1 2021.

Man Group reported no remaining Prevail Therapeutics Inc. Common Stock position as of Q1 2021 after selling out during the quarter.
Man Group sold 200,000 Prevail Therapeutics Inc. Common Stock shares in Q1 2021, an estimated $4.61M.
Man Group first reported a position in Prevail Therapeutics Inc. Common Stock in Q4 2020 and held it in 1 quarter.
Man Group's Prevail Therapeutics Inc. Common Stock position peaked at $4.61M in Q4 2020.
0 funds tracked by Wall St. Rank held Prevail Therapeutics Inc. Common Stock as of Q1 2021.

Based on Man Group's 13F filing for Q1 2021, filed 17 May 2021.